Healthcare Industry News: abdominal aortic aneurysm
News Release - July 16, 2008
Endologix Appoints Vice President of SalesIRVINE, Calif.--(HSMN NewsFeed)--Endologix, Inc. (Nasdaq:ELGX ), developer of the Powerlink® System for the minimally invasive treatment of abdominal aortic aneurysms (AAA), announces the appointment of Joseph A. DeJohn as Vice President of Sales, effective immediately. Mr. DeJohn brings more than 20 years of sales management experience in the medical device industry, including serving in senior positions in the peripheral vascular device division at C.R. Bard Corporation.
“Joe brings a strong track record of building and leading high-performing sales teams in the vascular industry,” said John McDermott, Endologix President and Chief Executive Officer. “From my experience working with Joe, I can attest that he is a results-oriented leader with a breadth of experience in hiring, training, developing and retaining medical device sales professionals. We expect to tap Joe’s proven capability to lead our sales force and gain market share with the Powerlink System. Joe will be working with a talented and dedicated sales management team that has successfully positioned Endologix for solid continued growth. I am delighted to welcome him to our senior management team.”
During his 17-year tenure at C.R. Bard Corporation, Mr. DeJohn held sales management positions with increasing responsibilities, serving the past six years as Vice President of Sales of the Peripheral Vascular Division. In this position, he was responsible for driving revenues through his management of a 200-person sales organization, playing a leadership role in strategic planning, budgeting, recruitment, professional development, national accounts and customer service. Prior to that, he was Director of Sales of the Peripheral Technologies Division, responsible for managing a 62-person sales organization and implementing a substantial sales force expansion. Before joining C.R. Bard Corporation, Mr. DeJohn served five years with Bausch & Lomb Corporation in various sales management positions. He received a B.S. in education from Bowling Green State University.
Endologix, Inc. develops and manufactures minimally invasive treatments for vascular diseases. Endologix's Powerlink System is an endoluminal stent graft for treating abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix’s Web site at www.endologix.com.
Except for historical information contained herein, this news release contains forward-looking statements relating to the continued growth of Endologix’s business and an increasing share of the endovascular AAA market, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. The Company undertakes no obligation to update its forward looking statements. Please refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2007, and the Company’s other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.